The global circulating tumor cells (CTC) liquid biopsy market is experiencing significant growth during the forecast period of 2023-2030. The market is driven by the growing demand for CTC liquid biopsy due to its effectiveness in cancer detection and monitoring. The increasing prevalence of cancer, influenced by genetic disorders, lifestyle changes, and alcohol consumption, further boosts the market's growth. The utilization of CTC for patient screening and preclinical studies of cancer drugs adds to its popularity. The introduction of nanotechnology for improved sensitivity and efficiency, widespread adoption of CTC-based liquid biopsy, and rising demand for minimally invasive diagnostic procedures contribute to the market's expansion.
According to Data Bridge Market Research the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
“Rising prevalence of cancer facilitate market growth”
The rising prevalence of cancer is a major driver of the global circulating tumor cells (CTC) liquid biopsy market. Cancer remains a significant global health concern, with increasing cases reported each year. Liquid biopsies offer a non-invasive and convenient approach for early cancer detection, monitoring treatment response, and assessing disease progression. The ability to capture and analyze CTCs from blood samples provides valuable insights into tumor biology and personalized treatment strategies. As the demand for accurate and efficient cancer diagnostics and monitoring tools grows, the CTC liquid biopsy market is expected to experience significant growth in the coming years.
What restraints the growth of the global circulating tumor cells (CTC) liquid biopsy market?
“The lower sensitivity of certain liquid biopsies”
The lower sensitivity of certain liquid biopsies is a significant restraint of the global circulating tumor cells (CTC) liquid biopsy market. While liquid biopsies offer non-invasive and convenient methods for cancer detection and monitoring, their sensitivity can vary depending on the type and stage of cancer. In some cases, the level of circulating tumor cells in the blood may be too low to be reliably detected, leading to false-negative results. Improving the sensitivity and accuracy of liquid biopsies is crucial to address this limitation and enhance their clinical utility in cancer diagnostics and treatment monitoring.
Segmentation: Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen, and end user.
- On the basis of technology, the circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, EX vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation models, microchips, single spiral microchannel, negative selection and immunocytochemical technologies.
- On the basis of application, the circulating tumor cells (CTC) liquid biopsy market is segmented into cancer application, non-cancer applications, non-invasive prenatal testing (NIPT), organ transplantation infectious disease testing.
- On the basis of clinical application, the circulating tumor cells (CTC) liquid biopsy market is segmented into early cancer screening, diagnosis, therapy selection, treatment monitoring, prognosis and recurrence monitoring.
- On the basis of sample type, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, urine, saliva, cerebrospinal fluid, others.
- On the basis of product, the circulating tumor cells (CTC) liquid biopsy market is segmented into kits and reagents, blood collection tubes, devices or system.
- On the basis of specimen, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, bone marrow, and other body fluids.
- On the basis of end user, the circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals, and physician laboratories.
Regional Insights: North America dominates the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
North America holds a dominant position in the global circulating tumor cells (CTC) liquid biopsy market, primarily driven by the widespread adoption of liquid biopsy techniques for cancer diagnosis in the region. The rising incidence of cancer cases in the US has contributed significantly to North America's market leadership. The region's advanced healthcare infrastructure and a strong emphasis on early cancer detection and personalized medicine have further bolstered the adoption of liquid biopsy technologies.
Asia Pacific is projected to witness substantial growth during the forecast period from 2023 to 2030. The market's expansion in this region is attributed to various factors, including increasing disposable income, growing awareness about liquid biopsy techniques, and greater adoption of advanced diagnostic technologies in hospitals, clinics, and diagnostic laboratories. Additionally, the rising healthcare expenditure and improved accessibility to hospitals and diagnostic centers are driving the adoption of liquid biopsy methods, further fueling the market's growth in the Asia Pacific.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
世界の循環腫瘍細胞（CTC）液体生検市場の最近の動向
- 2021年11月、ミリアド・ジェネティクス社はサンアントニオ乳がんシンポジウムでデータ発表を行い、乳がん治療における遺伝子検査の価値を強調しました。この発表により、ミリアド・ジェネティクス社は市場に新たな製品を導入し、リキッドバイオプシー市場の成長に貢献することになります。
- メナリニ・シリコン・バイオシステムズは2021年2月、循環腫瘍細胞の手動濃縮および染色を目的としたCellMag製品ラインを発売しました。この製品ラインの拡充により、メナリニ・シリコン・バイオシステムズの市場における地位は強化され、リキッドバイオプシー市場の成長に大きな影響を与えると期待されています。
世界の循環腫瘍細胞（CTC）液体生検市場で活動している主な主要企業は次のとおりです。
- QIAGEN（ドイツ）
- バイオテクネ（米国）
- プレシジョン・メディカル・グループLLC（米国）
- アビバ・システムズ・バイオロジカル・コーポレーション（米国）
- バイオセプト社（米国）
- Fluxion Biosciences, Inc.（米国）
- Greiner Bio-One International GmbH（オーストリア）
- アイコニシス（米国）
- ミルテニー・バイオテック（ドイツ）
- IVDiagnostics（米国）
- バイオフルイディカ（米国）
- カノープスメディカル（スウェーデン）
- バイオリディクス・リミテッド（シンガポール）
- クリエイティブ・マイクロテック社（米国）
- ラングライフAI社（米国）
- エピック・サイエンス（米国）
- Rarecells Diagnostics（フランス）
- スクリーンセル（フランス）
- メナリニ・シリコン・バイオシステムズ（米国）
上記はレポートで取り上げられている主要企業です。世界の循環腫瘍細胞（CTC）液体生検市場の企業に関する詳細なリストについては、 https://www.databridgemarketresearch.com/contact にお問い合わせください。
調査方法：世界の循環腫瘍細胞（CTC）液体生検市場
データ収集と基準年分析は、大規模なサンプルサイズを持つデータ収集モジュールを用いて行われます。市場データは、市場統計モデルとコヒーレントモデルを用いて分析・推定されます。さらに、市場シェア分析と主要トレンド分析は、本市場レポートの主要な成功要因となっています。DBMR調査チームが用いる主要な調査手法は、データマイニング、データ変数の市場への影響分析、そして一次（業界専門家）検証を含むデータ三角測量です。これ以外にも、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、企業市場シェア分析、測定基準、グローバルvs地域別、ベンダーシェア分析などのデータモデルが用意されています。詳細につきましては、アナリストコールをご依頼ください。
